Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BICALUTAMIDE for Hormone-refractory prostate cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 87 adverse event reports in the FDA FAERS database where BICALUTAMIDE was used for Hormone-refractory prostate cancer.

Most Reported Side Effects for BICALUTAMIDE

Side Effect Reports % Deaths Hosp.
Malignant neoplasm progression 352 8.7% 52 43
Prostatic specific antigen increased 322 7.9% 18 41
Drug ineffective 268 6.6% 46 38
Fatigue 258 6.4% 22 79
Prostate cancer 258 6.4% 35 74
Asthenia 223 5.5% 6 57
Hot flush 219 5.4% 10 21
Off label use 171 4.2% 21 51
Disease progression 169 4.2% 26 28
Anaemia 164 4.0% 35 86
Death 164 4.0% 164 24
Metastases to bone 164 4.0% 26 23
Dyspnoea 128 3.2% 15 61
Nausea 127 3.1% 5 45
Interstitial lung disease 118 2.9% 41 65

Other Indications for BICALUTAMIDE

Prostate cancer (1,832) Product used for unknown indication (732) Prostate cancer metastatic (338) Antiandrogen therapy (45) Metastases to bone (38) Hormone-dependent prostate cancer (32) Salivary gland cancer (31) Prostatic specific antigen increased (25) Hormone therapy (21) Adenocarcinoma (20)

Other Drugs Used for Hormone-refractory prostate cancer

ENZALUTAMIDE (8,881) RADIUM RA-223 DICHLORIDE (1,615) ABIRATERONE (1,378) DOCETAXEL (674) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (579) DAROLUTAMIDE (553) CABAZITAXEL (524) PREDNISONE (474) APALUTAMIDE (365) OLAPARIB (313)

Related Pages

BICALUTAMIDE Full Profile All Hormone-refractory prostate cancer Drugs BICALUTAMIDE Demographics BICALUTAMIDE Timeline